ME02477B - Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji - Google Patents
Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapijiInfo
- Publication number
- ME02477B ME02477B MEP-2016-163A MEP16316A ME02477B ME 02477 B ME02477 B ME 02477B ME P16316 A MEP16316 A ME P16316A ME 02477 B ME02477 B ME 02477B
- Authority
- ME
- Montenegro
- Prior art keywords
- therapeutic agent
- treatment
- use according
- compound
- effective amount
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Molecular Biology (AREA)
Claims (19)
1. Prvi terapijski agens predstavljen sledećom strukturalnom formulom: ili farmaceutski prihvatljiva so od toga, naznačeni time što su za korišćenje u lečenju Gošeove bolesti,u čemu pomenuto lečenje obuhvata primenu delotvorne količine prvog terapijskog agensa u kombinaciji sa delotvornom količinom drugog terapijskog agensa koji je delotvoran za lečenje Gošeove bolesti.
2. Korišćenje prvog terapijskog agensa predstavljenog sledećom strukturalnom formulom: ili farmaceutski prihvatljive soli od toga, naznačeno time što je za proizvodnju medikamenta za korišćenje u lečenju Gošeove bolesti, u čemu pomenuto lečenje obuhvata primenu delotvorne količine prvog terapijskog agensa u kombinaciji sa delotvornom količinom drugog terapijskog agensa koji je delotvoran za lečenje Gošeove bolesti.
3. Jedinjenje za korišćenje prema Patentnom zahtevu 1 ili korišćenje prema Patentnom zahtevu 2, naznačeno time što se drugi terapijski agens odabere između glukocerebrozidaze, analoga glukocerebrozidaze, inhibitora glukozilceramid sintaze i molekulskih šaperona koji se vežu na glukocerebrozidazu i obnavljaju njenu ispravnu konformaciju.
4. Jedinjenje za korišćenje prema Patentnom zahtevu 1 ili korišćenje prema Patentnom zahtevu 2, naznačeno time što drugi terapijski agens je imigluceraza, izofagomin, miglustat, taligluceraza alfa ili velagluceraza alfa.
5. Prvi terapijski agens predstavljen sa sledećom strukturalnom formulom: ili farmaceutski prihvatljiva so od toga, naznačeni time što su za korišćenje u lečenju Fabrijeve bolesti, u čemu pomenuto lečenje obuhvata primenu delotvorne količine prvog terapijskog agensa u kombinaciji sa delotvornom količinom drugog terapijskog agensa koji je delotvoran za lečenje Fabrijeve bolesti.
6. Korišćenje prvog terapijskog agensa predstavljenog sledećom strukturalnom formulom: ili farmaceutski prihvatljive soli od toga, naznačeno time što je za proizvodnju medikamenta za korišćenje u lečenju Fabrijeve bolesti, u čemu pomenuto lečenje obuhvata primenu delotvorne količine prvog terapijskog agensa u kombinaciji sa delotvornom količinom drugog terapijskog agensa koji je delotvoran za lečenje Fabrijeve bolesti.
7. Jedinjenje za korišćenje prema Patentnom zahtevu 5 ili korišćenje prema Patentnom zahtevu 6, naznačeni time što se drugi terapijski agens odabere između α galaktozidaze A, analoga α galaktozidaze A i molekulskih šaperona koji se vežu na α galaktozidazu A i obnavljaju njenu ispravnu konformaciju.
8. Jedinjenje za korišćenje prema Patentnom zahtevu 5 ili korišćenje prema Patentnom zahtevu 6, naznačeni time što drugi terapijski agens je migalastat, agalzidaza beta ili agalzidaza alfa.
9. Jedinjenje za korišćenje ili korišćenje prema bilo kojem od Patentnih zahteva 1 do 8, naznačeni time što se prvi terapijski agens primenjuje kao hemitartaratna so.
10. Jedinjenje za korišćenje ili korišćenje prema Patentnom zahtevu 9, naznačeni time što je pomenuta so amorfna ili je barem 70% težinski pomenute soli kristalno.
11. Jedinjenje za korišćenje ili korišćenje prema Patentnom zahtevu 9, naznačeni time što je barem 70% težinski pomenute soli u pojedinačnom kristalnom obliku.
12. Jedinjenje za korišćenje ili korišćenje prema Patentnom zahtevu 11, naznačeni time što je pojedinačni kristalni oblik karakterisan sa jednim, dva, tri, četiri ili pet glavnih vrhova difrakcije x-zraka na prahu pri 2θ uglovima od 5,1°, 6,6°, 10,7°, 11,0°, 15,9° i 21,7°.
13. Jedinjenje za korišćenje ili korišćenje prema Patentnom zahtevu 11, naznačeni time što je pojedinačni kristalni oblik karakterisan sa vrhovima difrakcije x-zraka na prahu pri 2θ uglovima od 5,1°, 6,6°, 10,7°, 11,0°, 13,3°, 15,1°, 15,9°, 16,5°, 17,6°, 18,6°, 18,7°, 19,0°, 20,2°, 21,7° i 23,5°.
14. Jedinjenje za korišćenje ili korišćenje prema Patentnom zahtevu 11, naznačeni time što je pojedinačni kristalni oblik is karakterisan sa uzorkom difrakcije x-zraka na prahu sa Slike 1.
15. Jedinjenje za korišćenje ili korišćenje prema bilo kojem od Patentnih zahteva 1 do 14, naznačeni time što se lečenje sa prvim terapijskim agensom otpočne nakon lečenja tokom perioda od barem deset sedmica sa drugim terapijskim agensom.
16. Jedinjenje za korišćenje ili korišćenje prema bilo kojem od Patentnih zahteva 1 do 14, naznačeni time što se lečenje sa prvim terapijskim agensom otpočne nakon lečenja sa drugim terapijskim agensom i u čemu se lečenje sa prvim terapijskim agensom otpočne nakon što je subjektov broj trombocita jednak ili veći od 100,000 mm3; koncentracija hemoglobina je jednaka ili veća od 11 g/dl (žensko) ili 12 g/dl (muško); i/ili je zapremina subjektove slezene manja od ili jednaka 10 količnika normale i zapremine jetre su manje od ili jednake 1,5 količnika normale.
17. Jedinjenje za korišćenje ili korišćenje prema Patentnom zahtevu 15 ili 16, naznačeni time što se lečenje sa drugim terapijskim agensom završi nakon početka lečenjenja sa prvim terapijskim agensom.
18. Jedinjenje za korišćenje ili korišćenje prema bilo kojem od Patentnih zahteva 1 do 17, naznačeni time što pomenuto lečenje obuhvata primenu prvog terapijskog agensa pri dvaput dnevno dozi od 25 miligrama do 200 miligrama.
19. Jedinjenje za korišćenje ili korišćenje prema bilo kojem od Patentnih zahteva 1 do 18, naznačeni time što pomenuto lečenje obuhvata primenu prvog terapijskog agensa pri dvaput dnevno dozi od 50 miligrama. Crteži
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26474809P | 2009-11-27 | 2009-11-27 | |
| EP14164650.5A EP2796457B1 (en) | 2009-11-27 | 2010-11-24 | Genz 112638 for treating Gaucher or Fabry disease in combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02477B true ME02477B (me) | 2017-02-20 |
Family
ID=43431870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-163A ME02477B (me) | 2009-11-27 | 2010-11-24 | Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji |
Country Status (40)
| Country | Link |
|---|---|
| US (6) | US11458119B2 (me) |
| EP (5) | EP3599237B1 (me) |
| JP (6) | JP2013512252A (me) |
| KR (6) | KR20220162824A (me) |
| CN (5) | CN105777707B (me) |
| AR (3) | AR079152A1 (me) |
| AU (3) | AU2010324810B2 (me) |
| BR (1) | BR112012012947B8 (me) |
| CA (3) | CA2781676C (me) |
| CL (2) | CL2012001348A1 (me) |
| CR (1) | CR20120277A (me) |
| CY (3) | CY1115880T1 (me) |
| DK (3) | DK3133070T3 (me) |
| DO (2) | DOP2012000141A (me) |
| EA (3) | EA029990B1 (me) |
| EC (2) | ECSP12011926A (me) |
| ES (4) | ES2586947T3 (me) |
| GT (1) | GT201200161A (me) |
| HR (3) | HRP20140780T4 (me) |
| HU (2) | HUE045784T2 (me) |
| IL (4) | IL310635A (me) |
| LT (2) | LT3133070T (me) |
| MA (1) | MA33838B1 (me) |
| ME (1) | ME02477B (me) |
| MX (2) | MX381242B (me) |
| MY (2) | MY160542A (me) |
| NI (1) | NI201200096A (me) |
| NZ (3) | NZ600155A (me) |
| PE (2) | PE20171255A1 (me) |
| PH (2) | PH12012501048A1 (me) |
| PL (4) | PL2504332T5 (me) |
| PT (4) | PT3599237T (me) |
| RS (3) | RS54978B1 (me) |
| SG (2) | SG10201407881WA (me) |
| SI (3) | SI2504332T2 (me) |
| SM (1) | SMT201600273B (me) |
| TN (1) | TN2012000237A1 (me) |
| TW (3) | TWI586663B (me) |
| UA (1) | UA113491C2 (me) |
| WO (1) | WO2011066352A1 (me) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| RS54978B1 (sr) | 2009-11-27 | 2016-11-30 | Genzyme Corp | Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji |
| WO2012177778A1 (en) * | 2011-06-20 | 2012-12-27 | Mount Sinai School Of Medicine | Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders |
| EP2753346B1 (en) | 2011-09-07 | 2020-04-22 | Mount Sinai School Of Medicine | Ceramidase and cell differentiation |
| WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
| SI2854910T1 (sl) | 2012-06-01 | 2020-09-30 | Icahn School Of Medicine At Mount Sinai | Nivoji ceramida pri zdravljenju in preprečevanju okužb |
| WO2014160390A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Therapeutic acid ceramidase compositions and methods of making and using them |
| CN105745206B (zh) * | 2013-09-20 | 2019-08-13 | 生物马林药物股份有限公司 | 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂 |
| CA2954030A1 (en) * | 2014-07-03 | 2016-01-07 | Dr. Reddy's Laboratories Limited | Amorphous form of eliglustat hemitartarate |
| ES2716420T3 (es) | 2015-04-14 | 2019-06-12 | Sandoz Ag | Clorhidrato de eliglustat cristalino |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| US11116755B2 (en) | 2015-11-18 | 2021-09-14 | Genzyme Corporation | Biomarker of polycystic kidney disease and uses thereof |
| US10696668B2 (en) | 2016-02-25 | 2020-06-30 | Asceneuron Sa | Acid addition salts of piperazine derivatives |
| CN107445938B (zh) * | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| CN106349210A (zh) * | 2016-08-24 | 2017-01-25 | 北京阳光诺和药物研究有限公司 | 一种制备酒石酸艾力骨司坦的方法 |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| WO2018193090A2 (en) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
| ZA201803719B (en) | 2017-06-05 | 2019-04-24 | Cipla Ltd | Stable solid dispersions of eliglustat hemitartrate |
| US11180478B2 (en) * | 2017-06-16 | 2021-11-23 | Beta Pharma, Inc. | Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| US12472144B2 (en) * | 2017-08-08 | 2025-11-18 | Amneal Pharmaceuticals Llc | Pharmaceutical composition comprising eliglustat |
| EP4647130A2 (en) * | 2017-08-08 | 2025-11-12 | Amneal Pharmaceuticals LLC | Pharmaceutical composition comprising eliglustat |
| EP3723809A1 (en) * | 2017-12-15 | 2020-10-21 | Genzyme Corporation | Methods for treating gaucher disease |
| US12064414B2 (en) | 2017-12-20 | 2024-08-20 | Aizant Drug Research Solutions Private Limited. | Stable amorphous Eliglustat premix and process for the preparation thereof |
| WO2019211778A2 (en) * | 2018-05-02 | 2019-11-07 | Kashiv Biosciences, Llc | Pro-drugs of eliglustat |
| JP2021525711A (ja) * | 2018-05-27 | 2021-09-27 | バイオアシス テクノロジーズ インコーポレイテッド | ゴーシェ病の処置 |
| CN110878079A (zh) * | 2018-12-31 | 2020-03-13 | 北京启慧生物医药有限公司 | 一种高纯度依利格鲁司他的制备方法 |
| US20240285615A1 (en) * | 2021-07-05 | 2024-08-29 | Asceneuron Sa | Medicaments comprising glycosidase inhibitors |
| CN116120274A (zh) * | 2021-11-12 | 2023-05-16 | 曙方(上海)医药科技有限公司 | 依利格鲁司他可药用盐及其晶型 |
| WO2026006099A1 (en) | 2024-06-24 | 2026-01-02 | Genzyme Corporation | Eliglustat for the treatment of gaucher disease |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8311286D0 (en) | 1983-04-26 | 1983-06-02 | Searle & Co | Carboxyalkyl peptide derivatives |
| DE3522475A1 (de) | 1985-06-22 | 1987-01-02 | Kali Chemie Pharma Gmbh | Neue aromatische verbindungen, ihre herstellung und verwendung |
| US5041441A (en) | 1988-04-04 | 1991-08-20 | The Regents Of The University Of Michigan | Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol |
| ZA929008B (en) | 1991-12-13 | 1993-05-21 | Bristol Myers Squibb Co | Piperazinyl- and piperidinyl-cyclohexanols. |
| US5302609A (en) | 1992-12-16 | 1994-04-12 | The Regents Of The University Of Michigan | Treatment of diabetic nephropathy |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| WO1995005177A1 (en) | 1993-08-13 | 1995-02-23 | Seikagaku Corporation | Remedy for nervous diseases |
| US6309823B1 (en) | 1993-10-26 | 2001-10-30 | Affymetrix, Inc. | Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same |
| PT742789E (pt) | 1994-02-02 | 2000-12-29 | Liposome Co Inc | Lipossomas e compostos farmaceuticamente activos e metodos para a sua utilizacao |
| DE69524592T2 (de) | 1994-06-10 | 2002-07-18 | Seikagaku Corp., Tokio/Tokyo | 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung |
| FR2734819B1 (fr) | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant |
| US6255336B1 (en) | 1995-09-20 | 2001-07-03 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| WO1997010817A1 (en) | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20030073680A1 (en) | 1995-09-20 | 2003-04-17 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| WO2001004108A1 (en) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| NO965193L (no) | 1995-12-08 | 1997-06-09 | Seikagaku Kogyo Kk Seikagaku C | Aminalkoholderivat og fremgangsmåte for fremstilling derav |
| JP3993908B2 (ja) | 1995-12-08 | 2007-10-17 | 生化学工業株式会社 | アミノアルコール誘導体及び該誘導体の製造方法 |
| JP4140984B2 (ja) | 1995-12-20 | 2008-08-27 | 生化学工業株式会社 | 分化誘導作用を有する薬剤 |
| US5972928A (en) | 1997-05-21 | 1999-10-26 | Johns Hopkins University | Methods for treatment of conditions associated with lactosylceramide |
| JP4036500B2 (ja) | 1997-05-23 | 2008-01-23 | 生化学工業株式会社 | アミノアルコール誘導体及びそれを含有する医薬 |
| JP4176170B2 (ja) | 1997-06-06 | 2008-11-05 | 生化学工業株式会社 | アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬 |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| ES2285852T3 (es) | 1998-07-27 | 2007-11-16 | Johns Hopkins University | Compuestos de diamino-propanol para el tratamiento de la isquemia. |
| US6610703B1 (en) | 1998-12-10 | 2003-08-26 | G.D. Searle & Co. | Method for treatment of glycolipid storage diseases |
| MXPA02000296A (es) * | 1999-07-09 | 2004-05-21 | Univ Michigan | Compuestos parecidos a aminoceramida y metodos de uso. |
| EP1384719A1 (en) | 1999-07-09 | 2004-01-28 | The Regents of The University of Michigan | Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections |
| BR0107456A (pt) * | 2000-01-07 | 2002-10-08 | Transform Pharmaceuticals Inc | Formação de amostras, métodos de preparar uma formação de múltiplas formas sólidas de um composto de interesse, de triar uma pluralidade de formas sólidas de um composto de interesse e condições e/ou componentes para compatibilidade com uma ou mais formas sólidas selecionadas de um composto de interesse, de identificar formas sólidas ótimas de um composto de interesse e de determinar conjuntos de condições e/ou componentes para produzir formas sólidas de um composto de interesse, um conjunto de parâmetros de processamento e/ou componentes e as condições e/ou componentes que produzem um composto de interesse ou um seu derivado diastereomérico e sistema para identificar formas sólidas ótimas de um composto de interesse |
| US20040252299A9 (en) | 2000-01-07 | 2004-12-16 | Lemmo Anthony V. | Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions |
| DE20122435U1 (de) | 2000-04-24 | 2005-10-06 | Teva Pharmaceutical Industries Ltd. | Mikronisiertes Zolpidem-Hemitartrat |
| US6436987B1 (en) | 2000-06-08 | 2002-08-20 | Pfizer Inc. | Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid |
| US7148251B2 (en) | 2001-01-10 | 2006-12-12 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20020198240A1 (en) | 2001-01-10 | 2002-12-26 | Shayman James A. | Amino ceramide - like compounds and therapeutic methods of use |
| CA2434028C (en) | 2001-01-10 | 2010-11-09 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| US20040260099A1 (en) | 2001-01-10 | 2004-12-23 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| PL362394A1 (en) | 2001-01-18 | 2004-11-02 | Merck Patent Gmbh | Bifunctional fusion proteins with glucocerebrosidase activity |
| DK2266968T3 (da) | 2001-07-16 | 2013-04-08 | Genzyme Corp | Syntese af UDP-glucose: N-acylsphingosin-glucosyltransferase-hæmmere |
| EP1281755A3 (en) | 2001-07-31 | 2003-06-18 | Pfizer Products Inc. | Variants of the human cyp2d6 gene |
| DE60235632D1 (de) | 2001-08-08 | 2010-04-22 | Tobira Therapeutics Inc | Bicyclische verbindung, deren herstellung und verwendung |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US20060217560A1 (en) | 2002-04-29 | 2006-09-28 | Shayman James A | Amino ceramide-like compounds and therapeutic methods of use |
| US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
| WO2004004702A2 (en) | 2002-07-09 | 2004-01-15 | The Scripps Research Institute | Method to inhibit ischemia and reperfusion injury |
| US20050032070A1 (en) | 2003-08-05 | 2005-02-10 | Sebastian Raimundo | Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications |
| ATE504588T1 (de) * | 2004-01-27 | 2011-04-15 | Synthon Bv | Stabile salze von olanzapin |
| CA2580537C (en) | 2004-09-17 | 2015-04-21 | University Of Massachusetts | Compositions and their uses for lysosomal enzyme deficiencies |
| ES2825949T3 (es) | 2004-09-30 | 2021-05-17 | Vanda Pharmaceuticals Inc | Métodos para administrar iloperidona |
| WO2006040649A1 (en) | 2004-10-13 | 2006-04-20 | Pharmacia & Upjohn Company Llc | Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide |
| WO2006053043A2 (en) | 2004-11-10 | 2006-05-18 | Genzyme Corporation | Methods of treating diabetes mellitus |
| WO2007038676A2 (en) * | 2005-09-28 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of ladostigil tartrate |
| JP2009510163A (ja) * | 2005-10-03 | 2009-03-12 | マリンクロッド・インコーポレイテッド | ヘミ酒石酸および酒石酸ゾルピデム多形の製造方法 |
| MX2007016179A (es) | 2006-04-17 | 2008-03-11 | Teva Pharma | Formas cristalinas de o-desmetilvenlafaxina. |
| PT2032134E (pt) | 2006-05-09 | 2015-10-07 | Genzyme Corp | Métodos de tratamento da doença do fígado gorduroso |
| KR101271225B1 (ko) | 2006-10-31 | 2013-06-03 | 삼성디스플레이 주식회사 | 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법 |
| TWI314226B (en) | 2006-12-07 | 2009-09-01 | Ind Tech Res Inst | Piezoelectricity-driving optical lens module |
| EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| TW200836773A (en) * | 2007-01-12 | 2008-09-16 | Wyeth Corp | Tablet-in-tablet compositions |
| CA2682441A1 (en) | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of fabry disease using pharmacological chaperones |
| JP2010525084A (ja) * | 2007-04-26 | 2010-07-22 | アミカス セラピューティックス インコーポレイテッド | 薬理シャペロンを用いたリソソーム蓄積症治療のための投薬計画 |
| EP2594565B1 (en) * | 2007-05-31 | 2018-10-24 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| DE102007029581B4 (de) | 2007-06-26 | 2020-04-09 | GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) | Kraftfahrzeugdach und Kraftfahrzeugkarosserie |
| CA2718887A1 (en) | 2008-03-19 | 2009-09-24 | Existence Genetics Llc | Genetic analysis |
| WO2009117150A2 (en) | 2008-03-20 | 2009-09-24 | Genzyme Corporation | Method of treating lupus with ceramide derivatives |
| CA2782179C (en) | 2009-11-27 | 2020-06-23 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| RS54978B1 (sr) | 2009-11-27 | 2016-11-30 | Genzyme Corp | Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji |
| NZ715101A (en) | 2009-11-27 | 2017-07-28 | Adverio Pharma Gmbh | Method for producing methyl-{ 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate and its purification for use thereof as pharmaceutical substance |
| FR2953139B1 (fr) | 2009-11-27 | 2012-04-13 | Servier Lab | Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine |
| KR20140033432A (ko) | 2011-06-21 | 2014-03-18 | 노파르티스 아게 | (s)-피롤리딘-1,2-디카르복실산 2-아미드 1-(｛4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일｝-아미드)의 다형체 |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| JP6728842B2 (ja) | 2016-03-24 | 2020-07-22 | オムロン株式会社 | 光学計測装置 |
| CN107445938B (zh) | 2016-05-31 | 2020-04-03 | 北京启慧生物医药有限公司 | 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物 |
| WO2018193090A2 (en) | 2017-04-21 | 2018-10-25 | Amneal Pharmaceuticals Company Gmbh | Process for preparation of eliglustat hemitartrate and intermediates thereof |
-
2010
- 2010-11-24 RS RS20160645A patent/RS54978B1/sr unknown
- 2010-11-24 PL PL10785289T patent/PL2504332T5/pl unknown
- 2010-11-24 MY MYPI2012002297A patent/MY160542A/en unknown
- 2010-11-24 SI SI201030715T patent/SI2504332T2/sl unknown
- 2010-11-24 IL IL310635A patent/IL310635A/en unknown
- 2010-11-24 DK DK16175117T patent/DK3133070T3/da active
- 2010-11-24 PH PH1/2012/501048A patent/PH12012501048A1/en unknown
- 2010-11-24 EP EP19182732.8A patent/EP3599237B1/en active Active
- 2010-11-24 PT PT191827328T patent/PT3599237T/pt unknown
- 2010-11-24 KR KR1020227040651A patent/KR20220162824A/ko not_active Ceased
- 2010-11-24 NZ NZ600155A patent/NZ600155A/en unknown
- 2010-11-24 NZ NZ715108A patent/NZ715108A/en unknown
- 2010-11-24 PL PL19182732T patent/PL3599237T3/pl unknown
- 2010-11-24 EA EA201592195A patent/EA029990B1/ru not_active IP Right Cessation
- 2010-11-24 ME MEP-2016-163A patent/ME02477B/me unknown
- 2010-11-24 PL PL14164650T patent/PL2796457T3/pl unknown
- 2010-11-24 TW TW099140523A patent/TWI586663B/zh active
- 2010-11-24 KR KR1020207002751A patent/KR20200013105A/ko not_active Ceased
- 2010-11-24 CA CA2781676A patent/CA2781676C/en active Active
- 2010-11-24 PT PT107852899T patent/PT2504332E/pt unknown
- 2010-11-24 EA EA201270646A patent/EA023923B1/ru not_active IP Right Cessation
- 2010-11-24 LT LT16175117T patent/LT3133070T/lt unknown
- 2010-11-24 EP EP16175117.7A patent/EP3133070B1/en not_active Revoked
- 2010-11-24 MY MYPI2019004988A patent/MY192644A/en unknown
- 2010-11-24 RS RS20140446A patent/RS53503B2/sr unknown
- 2010-11-24 CA CA3075788A patent/CA3075788C/en active Active
- 2010-11-24 EP EP10785289.9A patent/EP2504332B2/en active Active
- 2010-11-24 UA UAA201207602A patent/UA113491C2/uk unknown
- 2010-11-24 CN CN201610219151.5A patent/CN105777707B/zh active Active
- 2010-11-24 SG SG10201407881WA patent/SG10201407881WA/en unknown
- 2010-11-24 ES ES14164650.5T patent/ES2586947T3/es active Active
- 2010-11-24 AR ARP100104348A patent/AR079152A1/es not_active Application Discontinuation
- 2010-11-24 DK DK10785289.9T patent/DK2504332T4/da active
- 2010-11-24 NZ NZ625712A patent/NZ625712A/en unknown
- 2010-11-24 ES ES10785289T patent/ES2493940T5/es active Active
- 2010-11-24 CN CN201080061535.XA patent/CN102712629B/zh active Active
- 2010-11-24 PT PT141646505T patent/PT2796457T/pt unknown
- 2010-11-24 EP EP21160074.7A patent/EP3896069A1/en active Pending
- 2010-11-24 JP JP2012541183A patent/JP2013512252A/ja active Pending
- 2010-11-24 HR HRP20140780TT patent/HRP20140780T4/hr unknown
- 2010-11-24 PH PH1/2015/502514A patent/PH12015502514B1/en unknown
- 2010-11-24 EP EP14164650.5A patent/EP2796457B1/en active Active
- 2010-11-24 PT PT161751177T patent/PT3133070T/pt unknown
- 2010-11-24 EA EA201890254A patent/EA201890254A3/ru unknown
- 2010-11-24 HU HUE16175117A patent/HUE045784T2/hu unknown
- 2010-11-24 TW TW106124135A patent/TWI656873B/zh active
- 2010-11-24 MX MX2017011301A patent/MX381242B/es unknown
- 2010-11-24 US US13/511,768 patent/US11458119B2/en active Active
- 2010-11-24 AU AU2010324810A patent/AU2010324810B2/en active Active
- 2010-11-24 KR KR1020127016671A patent/KR20120115972A/ko not_active Ceased
- 2010-11-24 ES ES16175117T patent/ES2754398T3/es active Active
- 2010-11-24 MX MX2012006083A patent/MX358345B/es active IP Right Grant
- 2010-11-24 PL PL16175117T patent/PL3133070T3/pl unknown
- 2010-11-24 SI SI201031252A patent/SI2796457T1/sl unknown
- 2010-11-24 CN CN201610218210.7A patent/CN105753846B/zh active Active
- 2010-11-24 PE PE2016002590A patent/PE20171255A1/es unknown
- 2010-11-24 CA CA3140959A patent/CA3140959A1/en active Pending
- 2010-11-24 KR KR1020187012588A patent/KR20180049255A/ko not_active Ceased
- 2010-11-24 RS RS20191404A patent/RS59543B1/sr unknown
- 2010-11-24 CN CN202010962639.3A patent/CN112521366A/zh active Pending
- 2010-11-24 SG SG10201800136QA patent/SG10201800136QA/en unknown
- 2010-11-24 KR KR1020247041119A patent/KR20250005503A/ko active Pending
- 2010-11-24 PE PE2012000717A patent/PE20121337A1/es not_active Application Discontinuation
- 2010-11-24 BR BR112012012947A patent/BR112012012947B8/pt active IP Right Grant
- 2010-11-24 TW TW105126084A patent/TWI606827B/zh active
- 2010-11-24 DK DK14164650.5T patent/DK2796457T3/en active
- 2010-11-24 LT LTEP14164650.5T patent/LT2796457T/lt unknown
- 2010-11-24 SI SI201031936T patent/SI3133070T1/sl unknown
- 2010-11-24 HU HUE14164650A patent/HUE029371T2/en unknown
- 2010-11-24 KR KR1020157030851A patent/KR102073207B1/ko active Active
- 2010-11-24 CN CN202010962663.7A patent/CN112521367B/zh active Active
- 2010-11-24 WO PCT/US2010/057952 patent/WO2011066352A1/en not_active Ceased
- 2010-11-24 ES ES19182732T patent/ES2875382T3/es active Active
-
2012
- 2012-05-18 TN TNP2012000237A patent/TN2012000237A1/en unknown
- 2012-05-20 IL IL219892A patent/IL219892A0/en unknown
- 2012-05-23 DO DO2012000141A patent/DOP2012000141A/es unknown
- 2012-05-24 CL CL2012001348A patent/CL2012001348A1/es unknown
- 2012-05-24 CR CR20120277A patent/CR20120277A/es unknown
- 2012-05-24 NI NI201200096A patent/NI201200096A/es unknown
- 2012-05-24 EC ECSP12011926 patent/ECSP12011926A/es unknown
- 2012-05-25 GT GT201200161A patent/GT201200161A/es unknown
- 2012-06-20 MA MA34989A patent/MA33838B1/fr unknown
-
2014
- 2014-08-28 CY CY20141100690T patent/CY1115880T1/el unknown
-
2015
- 2015-07-06 JP JP2015134942A patent/JP6370264B2/ja active Active
-
2016
- 2016-01-13 US US14/994,489 patent/US20160120842A1/en not_active Abandoned
- 2016-02-22 US US15/049,946 patent/US10888547B2/en active Active
- 2016-03-04 JP JP2016041843A patent/JP6452635B2/ja active Active
- 2016-04-22 AU AU2016202591A patent/AU2016202591B2/en active Active
- 2016-08-11 SM SM201600273T patent/SMT201600273B/it unknown
- 2016-08-17 CY CY20161100807T patent/CY1117996T1/el unknown
- 2016-08-17 HR HRP20161038TT patent/HRP20161038T1/hr unknown
- 2016-09-19 DO DO2016000250A patent/DOP2016000250A/es unknown
- 2016-10-12 CL CL2016002589A patent/CL2016002589A1/es unknown
-
2017
- 2017-11-27 AU AU2017265180A patent/AU2017265180B2/en active Active
-
2018
- 2018-06-27 IL IL260299A patent/IL260299A/en unknown
- 2018-08-23 EC ECSENADI201863798A patent/ECSP18063798A/es unknown
- 2018-09-07 JP JP2018167432A patent/JP7150528B2/ja active Active
-
2019
- 2019-09-12 HR HRP20191647 patent/HRP20191647T1/hr unknown
- 2019-11-13 CY CY20191101196T patent/CY1122698T1/el unknown
-
2020
- 2020-08-14 JP JP2020136889A patent/JP2020189873A/ja active Pending
-
2021
- 2021-01-07 US US17/143,821 patent/US20210369672A1/en not_active Abandoned
- 2021-03-18 AR ARP210100683A patent/AR121612A2/es not_active Application Discontinuation
- 2021-03-18 AR ARP210100682A patent/AR121611A2/es not_active Application Discontinuation
- 2021-06-13 IL IL283935A patent/IL283935A/en unknown
- 2021-09-03 US US17/465,994 patent/US20210393590A1/en not_active Abandoned
-
2022
- 2022-07-14 US US17/865,195 patent/US12465586B2/en active Active
-
2023
- 2023-06-21 JP JP2023101301A patent/JP2023116764A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02477B (me) | Genz 112638 za lečenje gošeove ili fabrijeve bolesti u kombinacionoj terapiji | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| HRP20180436T1 (hr) | Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| WO2013003629A3 (en) | Methods and compositions for inhibition of bone resorption | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| IL197393A (en) | History of pyridine-4-ram, containing and using pharmaceutical preparations for the preparation of drugs for the treatment of immune-related diseases | |
| HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
| ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| FI3494972T3 (fi) | Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| MX2008013212A (es) | 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r. | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2013516493A5 (me) | ||
| HRP20210474T1 (hr) | Režim primjene nitrokatehola | |
| RU2015135843A (ru) | Терапевтическое средство от грыжи межпозвоночного диска | |
| WO2008011426A3 (en) | Methods and medicaments for administration of ibuprofen | |
| MX2010009395A (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos. | |
| JP2013209384A5 (me) | ||
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| MX2009004579A (es) | Composicion farmaceutica que tiene actividad antisicotica, antidepresiva o antiepileptica, con efecto colateral reducido. |